Results 31 to 40 of about 10,182 (218)

Properdin levels in human sepsis [PDF]

open access: yesFrontiers in Immunology, 2015
Properdin is a normal serum protein which increases the production of complement activation products by binding to C3b integral to convertase complexes and amplifying their activity at the site of activation.
Cordula M Stover   +4 more
doaj   +4 more sources

Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family

open access: yesFrontiers in Endocrinology, 2018
BackgroundThere is increasing evidence for the role of impaired intestinal permeability in obesity and associated metabolic diseases. Zonulin is an established serum marker for intestinal permeability and identical to pre-haptoglobin2.
Lucas Scheffler   +11 more
doaj   +2 more sources

Properdin: A Novel Target for Neuroprotection in Neonatal Hypoxic-Ischemic Brain Injury

open access: yesFrontiers in Immunology, 2019
Background: Hypoxic-ischemic (HI) encephalopathy is a major cause of neonatal mortality and morbidity, with a global incidence of 3 per 1,000 live births.
Claudia Sisa   +5 more
doaj   +2 more sources

Corrigendum: HBSP improves kidney ischemia-reperfusion injury and promotes repair in properdin deficient mice via enhancing phagocytosis of tubular epithelial cells [PDF]

open access: goldFrontiers in Immunology, 2023
Yuanyuan Wu   +13 more
doaj   +2 more sources

Properdin [PDF]

open access: yesDefinitions, 2020
Properdin (469 aa, ~51 kDa) is encoded by the human CFP gene. This protein plays a role in the stabilization of complement convertases of the alternative pathway.
openaire   +2 more sources

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study. [PDF]

open access: yesClin Transl Sci
ABSTRACT Properdin is an endogenous positive regulator of the complement alternative pathway (AP). Tarperprumig (ALXN1820), a novel humanized bispecific antibody, binds properdin and albumin and is being developed to treat complement‐mediated diseases.
Sandhu A   +8 more
europepmc   +2 more sources

Functional and structural insight into properdin control of complement alternative pathway amplification [PDF]

open access: bronzeEMBO Journal, 2017
Dennis Pedersen   +11 more
openalex   +2 more sources

Seventy Years Later: Systemic and Local Properdin in Atherosclerosis [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Jean F. Regal, Sherry D. Fleming
doaj   +2 more sources

Home - About - Disclaimer - Privacy